An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the α_v<i>β</i>₃-selective angiogenesis imaging agent ^99mtc-nc100692

Abstract

Scintigraphy with (99m)Tc-NC100692 is feasible for detection of lung and brain metastases from breast and lung cancer, while the detection of liver and bone lesions is poor. The use of (99m)Tc-NC100692 is safe and well tolerated.